NCT05247489 - A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 5, 2022

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions

Vitiligo

Interventions

DRUG

Ruxolitinib 1.5% cream

Ruxolitinib cream 1.5% applied twice a day (BID).

DEVICE

NB-UVB phototherapy

NB-UVB (311-312 nm) phototherapy is an established treatment modality for vitiligo. Starting dose will be 200 mJ/cm2 and dose may be increased by 10% at each visit

Trial Locations (13)

20850

Aesthetic and Dermatology Center, Rockville

48202

Henry Ford Medical Center - New Center One, Detroit

70809

Delricht Clinical Research - Clinedge - Ppds Baton Rouge, Baton Rouge

78660

Austin Institute For Clinical Research Aicr Pflugerville, Pflugerville

92708

First Oc Dermatology, Fountain Valley

94086

Palo Alto Medical Foundation, Sunnyvale

95816

UC Davis Health, Sacramento

99202

Principle Research Solutions, Spokane

02111

Tufts Medical Center, Boston

02135

Metro Boston Clinical Partners, Brighton

01605

University of Massachusetts Medical School, Worcester

L4M 7G1

Simcomed Health Ltd, Barrie

L3P 1X2

Lynderm Research Inc, Markham